DECOY20 Study in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
INDP-D101 is a Phase 1, open-label, multi-center, dose escalation and expansion study
evaluating the safety, tolerability and clinical activity of Decoy20 in patients with
advanced solid tumors.